Ascendis Pharma stock maintains leadership as UBS reiterates Buy rating

Ascendis Pharma (ASND) has received reiterated 'Buy' ratings and strong price targets from UBS and Bank of America, following Q2 2025 results that significantly surpassed EPS and revenue expectations. Analysts maintain that Ascendis's Yorvipath retains market leadership in the $10 billion+ hypoparathyroidism space, despite positive competitor clinical data, citing superior efficacy. This positive outlook is further supported by anticipated Yorvipath sales growth, expanding payor coverage, and the upcoming launch of TransConCNP, signaling a path towards profitability.

Analysis

Ascendis Pharma (ASND) has demonstrated significant operational momentum, underscored by a strong Q2 2025 performance that materially beat consensus estimates. The company reported an EPS of -0.82, a 35.43% positive surprise against a forecast of -1.27, and revenue of €158 million, surpassing the expected €142.38 million. This financial outperformance coincides with strong analyst support from both UBS and Bank of America, which reiterated Buy ratings with price targets of $307 and $230, respectively. The bullish sentiment persists despite positive Phase 2 data from competitor MBX, whose treatment achieved a 63% primary endpoint response. Analysts at UBS view this as removing a competitive overhang, asserting that Ascendis's Yorvipath maintains clear market leadership with superior placebo-adjusted response rates (69% at 26 weeks). The long-term outlook is anchored by the large addressable market for hypoparathyroidism, estimated at over $10 billion, and a key pipeline catalyst in TransConCNP, which has a PDUFA date set for November 30, 2025, positioning the company on a path toward future profitability.

Key Decisions for Investors

• Given the strong earnings beat and reiterated 'Buy' ratings from key analysts, investors may view the current environment as supportive for maintaining or initiating long positions in ASND.
• Investors should closely monitor the sales trajectory and expansion of payor coverage for Yorvipath, as these are the primary near-term drivers for validating the company's growth thesis and path to profitability.
• The PDUFA date for TransConCNP on November 30, 2025, represents a significant future catalyst; portfolio positioning should account for the potential volatility and upside associated with this binary event.
• While analysts discount the immediate threat, it is prudent to track the clinical progress of MBX's canvuparatide as a key indicator of the long-term competitive dynamics in the hypoparathyroidism market.